Investigating the effects of bimagrumab on body composition and insulin sensitivity in adults with obesity
Effects of bimagrumab on body composition, insulin sensitivity, and bone in adults with obesity
This study is looking at how a new drug called bimagrumab can help adults with obesity lose fat while keeping their muscles and bones healthy, and it will also include some lifestyle changes to help with weight loss.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10898713 on NIH RePORTER |
What this research studies
This research focuses on how bimagrumab, a new drug, affects body composition, insulin sensitivity, and bone health in adults with obesity. The study aims to determine whether this medication can help individuals lose fat while preserving muscle and bone mass, which is crucial for overall health. Participants will be monitored for changes in body weight, fat distribution, and bone density, providing valuable insights into the drug's effectiveness. The approach includes a combination of lifestyle interventions and pharmacotherapy to achieve optimal weight loss outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who are struggling with obesity and related metabolic issues.
Not a fit: Patients who are not overweight or obese, or those who have contraindications to bimagrumab, may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved weight loss strategies that enhance metabolic health while protecting muscle and bone.
How similar studies have performed: Previous research has shown promising results with similar pharmacological approaches, suggesting potential for success with bimagrumab.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Haines, Melanie Schorr — Massachusetts General Hospital
- Study coordinator: Haines, Melanie Schorr
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.